TipRanks on MSN
Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study ...
TipRanks on MSN
Xenon Pharmaceuticals’ Phase 3 Study on XEN1101: A Potential Game-Changer in Seizure Treatment
Xenon Pharmaceuticals (($XENE)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Randomized, ...
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer This is a randomized, ...
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for ...
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT ...
IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus ...
WASHINGTON, Sept. 25, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback